The use of an IDH inhibitor in this context is supported by the INDIGO trial, which evaluated vorasidenib, an IDH1/2 inhibitor approved by the US Food and Drug Administration (FDA) in August 2024 for grade 2 IDH-mutant astrocytoma and oligodendroglioma. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).